Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee, Ivana N. M. Micallef, Patrick J. Stiff, Jonathan L. Kaufman, Richard T. Maziarz, Chitra Hosing, Stefan Früehauf, Mitchell Horwitz, Dennis Cooper, Gary Bridger, Gary Calandra, for the 3102 Investigators

Blood (2009) 113 (23): 5720–5726.

https://doi.org/10.1182/blood-2008-08-174946

Published: 2009

Journal Articles

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

John F. DiPersio, MD, PhD, Ivana NM Micallef, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 1136.

https://doi.org/10.1182/blood.V112.11.1136.1136

Published: 2008

Journal Articles

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

John F. DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, Ivana NM Micallef, MD, Patrick J. Stiff, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 3312.

https://doi.org/10.1182/blood.V112.11.3312.3312

Published: 2008

Journal Articles

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Patrick J. Stiff, MD, Ivana NM Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, MD, Richard Thomas Maziarz, MD, Brian J. Bolwell, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Jennifer Angell, MS, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 2175.

https://doi.org/10.1182/blood.V112.11.2175.2175

Published: 2008

Journal Articles

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

Steven M. Devine, Ravi Vij, Michael Rettig, Laura Todt, Kiley McGlauchlen, Nicholas Fisher, Hollie Devine, Daniel C. Link, Gary Calandra, Gary Bridger, Peter Westervelt, John F. DiPersio

Blood (2008) 112 (4): 990–998.

https://doi.org/10.1182/blood-2007-12-130179

Published: 2008

Journal Articles

The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.

Jonathan L. Kaufman, MD, Amanda M. Cook, CCRP, Christopher Flowers, MD, Amelia A. Langston, MD, Sagar Lonial, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, Gary Calandra, MD, Ned Waller, MD, PhD

Blood (2007) 110 (11): 1912.

https://doi.org/10.1182/blood.V110.11.1912.1912

Published: 2007

Journal Articles

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

Steven J. Lemery, MD, Matthew M. Hsieh, MD, Aleah Smith, Sheila Rao, Hanh M. Khuu, Donohue Theresa, PA, Jennifer M. Karpovich, NP, Lisa Cook, RN, Rose Goodwin, RN, Carol Boss, MPH, Gary Calandra, Nancy Geller, PhD, John Tisdale, MD, Richard Childs, MD

Blood (2007) 110 (11): 3278.

https://doi.org/10.1182/blood.V110.11.3278.3278

Published: 2007

Journal Articles

Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.

Ronald MacFarland, PhD, Reginal B. Ewesuedo, MD, Karin Badel, Gary Calandra, MD

Blood (2007) 110 (11): 2878.

https://doi.org/10.1182/blood.V110.11.2878.2878

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John F. DiPersio, MD, PhD, Ivana Micallef, MD, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, 3101 Investigators7

Blood (2007) 110 (11): 601.

https://doi.org/10.1182/blood.V110.11.601.601

Published: 2007

Journal Articles

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

Ivana Micallef, MD, Patrick J. Stiff, MD, John F. DiPersio, MD, PhD, Richard Thomas Maziarz, MD, John M. McCarty, MD, Jennifer Angell, MS, Gary Bridger, PhD, Gary Calandra, MD, on behalf of the 3101 Investigators7

Blood (2007) 110 (11): 602.

https://doi.org/10.1182/blood.V110.11.602.602

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Ivana Micallef, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, for the 3102 Investigators7

Blood (2007) 110 (11): 445.

https://doi.org/10.1182/blood.V110.11.445.445

Published: 2007

Journal Articles

Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.

Michael Andreeff, MD, PhD, Sergej Konoplev, M.D., Ph.D., Rui-Yu Wang, M.D., Ph.D., Zhihong Zeng, Ph.D., Teresa McQueen, Yue-Xi Shi, L. Jeffrey Medeiros, M.D., Elihu Estey, M.D., John M. McCarty, M.D., Stephanie Elkins, M.D., Richard Champlin, M.D., Gary Calandra, M.D., Ph.D., Gary Bridger, Ph.D., Marina Konopleva, M.D., Ph.D.

Blood (2006) 108 (11): 568.

https://doi.org/10.1182/blood.V108.11.568.568

Published: 2006

Journal Articles

Rescue from Failed Growth Factor and/or Chemotherapy HSC Mobilization with G-CSF and AMD3100: An Institutional Experience.

Richard Thomas Maziarz, MD, Adam Dunn, BS, Lisa Hansen, RN, Keith Hansen, MD, Jose F. Leis, MD, PhD, Brandon Hayes-Lattin, MD, Tibor Kovacsovics, MD, Gary Calandra, MD, Cedar Fowler, BA

Blood (2006) 108 (11): 5460.

https://doi.org/10.1182/blood.V108.11.5460.5460

Published: 2006

Journal Articles

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

Steven M. Devine, MD, Ravi Vij, MD, Laura Todt, RN, Kiley McLaughlin, BS, Nicholas Fisher, BA, Natalie Morris, Daniel C. Link, MD, Gary Calandra, MD, Gary Bridger, PhD, John F. DiPersio, MD, PhD

Blood (2006) 108 (11): 53.

https://doi.org/10.1182/blood.V108.11.53.53

Published: 2006

Journal Articles

AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.

Gary Calandra, John McCarty, Joseph McGuirk, Bart Barlogie, Sue-Anne Crocker, Karin Badel

Blood (2006) 108 (11): 5218.

https://doi.org/10.1182/blood.V108.11.5218.5218

Published: 2006

Journal Articles

Steady State Mobilization of Autologous Blood Stem Cells Using G-CSF and AMD3100 in Patients with Multiple Myeloma (MM).

Gerhard Ehninger, Stefan Fruehauf, Kai Hubel, Uwe Platzbecker, Karin Badel, Gary Calandra

Blood (2006) 108 (11): 5219.

https://doi.org/10.1182/blood.V108.11.5219.5219

Published: 2006

Journal Articles

A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin’s Disease, and PK Is Similar to That of Non-Cancer Patients.

Amanda F. Cashen, MD, Gary Calandra, M.D., Ph.D., Ron MacFarland, Ph.D., Sandra Lopez, M.D., John F. DiPersio, M.D., Ph.D.

Blood (2006) 108 (11): 3053.

https://doi.org/10.1182/blood.V108.11.3053.3053

Published: 2006

Journal Articles

Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).

Neal Flomenberg, MD, Raymond Comenzo, MD, Karin Badel, Gary Calandra, MD

Blood (2006) 108 (11): 3381.

https://doi.org/10.1182/blood.V108.11.3381.3381

Published: 2006

Journal Articles

AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).

Stewart Douglas, Clayton Smith, Ron McFarland, Karin Badel, Gary Calandra

Blood (2006) 108 (11): 3383.

https://doi.org/10.1182/blood.V108.11.3383.3383

Published: 2006

Journal Articles

AMD3100 Inhibits Chemotaxis towards SDF-1 and CXCR4-Mediated Stroma-Contact in a Dose-Dependent Manner, Resulting in Increased Susceptibility to Imatinib.

Falk M. Dillmann, Marlon R. Veldwijk, Gary Calandra, Werner J. Zeller, Anthony D. Ho, Stefan Fruehauf

Blood (2006) 108 (11): 4799.

https://doi.org/10.1182/blood.V108.11.4799.4799

Published: 2006

NARROW

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.

Rescue from Failed Growth Factor and/or Chemotherapy HSC Mobilization with G-CSF and AMD3100: An Institutional Experience.

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.

Steady State Mobilization of Autologous Blood Stem Cells Using G-CSF and AMD3100 in Patients with Multiple Myeloma (MM).

A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin’s Disease, and PK Is Similar to That of Non-Cancer Patients.

Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).

AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).

AMD3100 Inhibits Chemotaxis towards SDF-1 and CXCR4-Mediated Stroma-Contact in a Dose-Dependent Manner, Resulting in Increased Susceptibility to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only